Uncategorized

En este Short escucharemos qué sonido hace un torbellino de polvo en la superficie de Marte.     …

Boehringer Ingelheim reported a strong performance in 2022, a year in which 30 million patients benefited from its innovative medicines, while deepening investments in the search for new treatments.

SciBase Holding AB, a leading developer of augmented intelligence-based solutions for skin disorders announced that they have entered into a collaboration agreement with Schweiger Dermatology group to pilot Nevisense in their Freehold, NJ office.

Genialis announced it raised more than $13 million in Series A financing to transform the way diseases are diagnosed and treatment decisions are made.

Mainz Biomed NV announced results of an independent feasibility study conducted in collaboration with members of the Early Detection Research Network to evaluate the Company’s portfolio of five novel gene expression biomarkers acquired from Université de Sherbrooke in January, 2022.

Transcenta Holding Limited announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Osemitamab, its high affinity humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody, for the treatment of patients with pancreatic cancer.

Avivagen Inc. announces that pursuant to its previously announced “Securities for Services” agreements with Top Meadow Consulting Services Inc. and Mr. Graham Burton, the Company has issued an aggregate of 507,345 common shares in the capital of the Company to Top Meadow Consulting Services Inc. and Mr. Graham Burton.

Pharmaron Beijing Co., Limited announced that their Liverpool, UK based Gene Therapy CDMO has received a prestigious grant from the UK Government’s Life Sciences Innovation Manufacturing Fund to expand their viral vector and DNA manufacturing facilities for more than 8,000 sqM.

OKYO Pharma Limited announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 12,500 of the Company’s ADSs on NASDAQ at a price of US$1.32 per ADS at a price of £0.0165 each).

Medigene AG, an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported financial results for the year ended December 31, 2022 and provided a corporate update.